Abpro Stock Surges 3,210%, With A 8-Day Winning Spree
Abpro (ABP) stock hit day 8 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 3,210% return. The company has gained about $11 Mil in value over the last 8 days, with its current market capitalization at about $12 Mil. The stock remains 88.8% below its value at the end of 2024. This compares with year-to-date returns of 16.5% for the S&P 500.
Abpro’s recent streak was ignited by compelling preclinical data for its HER2/CD3 bispecific antibody, CT-P72/ABP-102. The novel cancer therapy, co-developed with Celltrion, demonstrated potent anti-tumor activity even against resistant strains, fueling investor excitement for its potential clinical advancement.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.Nevertheless, Stock-picking thrills fade fast when volatility hits. Smart financial advisors stay ahead by combining insights with action, channeling client capital into diversified portfolios that perform across cycles.
For quick background, ABP
Comparing ABP Stock Returns With The S&P 500
The following table summarizes the return for ABP stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | ABP | S&P 500 |
|---|---|---|
| 1D | 0.8% | 0.1% |
| 8D (Current Streak) | 3209.5% | 0.2% |
| 1M (21D) | 5.8% | 3.1% |
| 3M (63D) | -20.1% | 5.9% |
| YTD 2025 | -88.8% | 16.5% |
| 2024 | 23.3% | |
| 2023 | 24.2% | |
| 2022 | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 113 S&P constituents with 3 days or more of consecutive gains and 13.0 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 30 | 13 |
| 4D | 47 | 0 |
| 5D | 17 | 0 |
| 6D | 11 | 0 |
| 7D or more | 8 | 0 |
| Total >=3 D | 113 | 13 |
Key Financials for Abpro (ABP)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0.1 Mil | $0.2 Mil |
| Operating Income | $-11.7 Mil | $-9.9 Mil |
| Net Income | $-11.7 Mil | $-7.2 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-3.0 Mil | $-2.3 Mil |
| Net Income | $-3.9 Mil | $-3.0 Mil |
While ABP stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.